Emisphere announces $20 million debt financing to launch oral Eligen(R) B12
Emisphere announced an agreement with MHR Fund Management to finance the launch of the Company's first prescription product, oral Eligen® B12 in the U.S. through a new loan facility. Emisphere may borrow up to $20 million to finance development, manufacturing, marketing and sales of the B12 Product. August 20, 2014